WallStreetZenWallStreetZen

NYSE: OGN
Organon & Co Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their OGN stock forecasts and price targets.

Forecast return on equity

Is OGN forecast to generate an efficient return?

Company
100.19%
Industry
0.07%
Market
175.22%
OGN's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is OGN forecast to generate an efficient return on assets?

Company
7.65%
Industry
26.81%
OGN is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

OGN earnings per share forecast

What is OGN's earnings per share in the next 3 years based on estimates from 8 analysts?

Avg 1 year Forecast
$3.45+337.04%
Avg 2 year Forecast
$3.68+365.54%
Avg 3 year Forecast
$3.86+388.63%
OGN's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

OGN revenue forecast

What is OGN's revenue in the next 3 years based on estimates from 8 analysts?

Avg 1 year Forecast
$6.2B+1.22%
Avg 2 year Forecast
$6.3B+2.95%
Avg 3 year Forecast
$6.4B+3.85%
OGN's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

OGN earnings growth forecast

How is OGN forecast to perform vs Drug Manufacturers - General companies and vs the US market?

Company
69.82%
Industry
39.11%
Market
32.56%
OGN's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
OGN's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
OGN's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

OGN revenue growth forecast

How is OGN forecast to perform vs Drug Manufacturers - General companies and vs the US market?

Company
1.32%
Industry
6.5%
Market
12.98%
OGN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
OGN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

OGN vs General Drug Manufacturer Stocks

TickerPricePrice TargetUp/downsideConsensus
OGN$13.81N/AN/A
GRFS$8.04$9.00+11.94%Hold
AMRN$12.74$13.00+2.08%Strong Sell
NSRX$3.19N/AN/A
MIRA$0.57$3.50+511.89%Strong Buy
View Top General Drug Manufacturer Stocks

Organon & Co Stock Forecast FAQ

What is OGN's earnings growth forecast for 2026-2028?

(NYSE: OGN) Organon & Co's forecast annual earnings growth rate of 69.82% is forecast to beat the US Drug Manufacturers - General industry's average forecast earnings growth rate of 39.11%, and it is also forecast to beat the US market's average forecast earnings growth rate of 32.56%.

Organon & Co's earnings in 2026 is $209,000,000.On average, 8 Wall Street analysts forecast OGN's earnings for 2026 to be $906,685,328, with the lowest OGN earnings forecast at $849,278,906, and the highest OGN earnings forecast at $1,025,752,445. On average, 8 Wall Street analysts forecast OGN's earnings for 2027 to be $965,824,973, with the lowest OGN earnings forecast at $877,588,203, and the highest OGN earnings forecast at $1,053,326,436.

In 2028, OGN is forecast to generate $1,013,724,933 in earnings, with the lowest earnings forecast at $898,176,783 and the highest earnings forecast at $1,119,504,013.

If you're new to stock investing, here's how to buy Organon & Co stock.

What is OGN's revenue growth forecast for 2026-2028?

(NYSE: OGN) Organon & Co's forecast annual revenue growth rate of 1.32% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 6.5%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 12.98%.

Organon & Co's revenue in 2026 is $6,127,000,000.On average, 8 Wall Street analysts forecast OGN's revenue for 2026 to be $1,628,703,703,466, with the lowest OGN revenue forecast at $1,545,193,903,772, and the highest OGN revenue forecast at $1,710,375,237,129. On average, 8 Wall Street analysts forecast OGN's revenue for 2027 to be $1,656,540,303,364, with the lowest OGN revenue forecast at $1,541,517,371,710, and the highest OGN revenue forecast at $1,775,764,985,946.

In 2028, OGN is forecast to generate $1,670,983,822,179 in revenue, with the lowest revenue forecast at $1,534,952,135,885 and the highest revenue forecast at $1,841,417,344,196.

What is OGN's forecast return on assets (ROA) for 2026-2029?

(NYSE: OGN) forecast ROA is 7.65%, which is lower than the forecast US Drug Manufacturers - General industry average of 26.81%.

What is OGN's Earnings Per Share (EPS) forecast for 2026-2028?

(NYSE: OGN) Organon & Co's current Earnings Per Share (EPS) is $0.79. On average, analysts forecast that OGN's EPS will be $3.45 for 2026, with the lowest EPS forecast at $3.23, and the highest EPS forecast at $3.91. On average, analysts forecast that OGN's EPS will be $3.68 for 2027, with the lowest EPS forecast at $3.34, and the highest EPS forecast at $4.01. In 2028, OGN's EPS is forecast to hit $3.86 (min: $3.42, max: $4.26).

What is OGN's forecast return on equity (ROE) for 2026-2029?

(NYSE: OGN) forecast ROE is 100.19%, which is considered strong.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.